Residency · Residency · Vascular Surgery
Management of Asymptomatic Carotid Stenosis in the Modern Era
Overview
The management of asymptomatic carotid stenosis remains one of the most actively debated topics in vascular surgery today. Historical trials such as ACAS and ACST-1 demonstrated that carotid endarterectomy (CEA) provided a benefit over medical therapy; however, these studies were conducted when medical therapy was far less advanced than it is now. With the advent of modern best medical therapy (BMT), the annual stroke risk in asymptomatic patients has substantially decreased. This raises the central question: does the benefit of revascularization—whether by CEA, carotid artery stenting (CAS), or transcarotid artery revascularization (TCAR)—still outweigh the risks in the era of optimal medical therapy? Contemporary trials like CREST-2 and ACST-2 are pivotal in addressing this question.
Historical Context
The Asymptomatic Carotid Atherosclerosis Study (ACAS) in 1995 enrolled patients with asymptomatic stenosis of 60% or greater and found that CEA reduced the 5-year stroke risk from 11% to 5.1%, yielding an absolute risk reduction (ARR) of 5.9% over five years, or roughly a 1% annual risk reduction. However, the medical therapy used in ACAS was suboptimal by today’s standards, lacking widespread use of statins and consistent antiplatelet therapy.
Similarly, the Asymptomatic Carotid Surgery Trial-1 (ACST-1), published in 2004 with updates in 2010, showed that CEA reduced the 5-year stroke risk from 11.8% to 6.4% in patients with stenosis of 60% or greater. The benefit was primarily seen in patients younger than 75 years. Again, medical therapy in this trial was not optimized according to current standards.
These historical trials have important limitations. Statin use was less than 20% in ACAS and about 30% in ACST-1. Modern antiplatelet therapy was inconsistently applied, blood pressure control was less aggressive, and smoking cessation programs were less developed. Therefore, the "medical therapy" arms in these trials do not reflect current clinical practice.
Modern Best Medical Therapy (BMT)
Modern best medical therapy for asymptomatic carotid stenosis includes several key components. High-intensity statin therapy, such as atorvastatin 40-80 mg or rosuvastatin 20-40 mg, aims to reduce low-density lipoprotein (LDL) cholesterol to below 70 mg/dL, or ideally below 55 mg/dL according to European guidelines. Beyond LDL lowering, statins stabilize atherosclerotic plaques, reduce inflammation, and improve endothelial function. Antiplatelet therapy typically involves aspirin at doses of 81-325 mg daily, with clopidogrel as an alternative for those intolerant to aspirin. Blood pressure control targets a level below 130/80 mmHg, with angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) preferred. Smoking cessation is supported by pharmacotherapy and counseling, while diabetes management focuses on optimizing HbA1c levels. Lifestyle modifications such as adherence to a Mediterranean diet and regular physical activity are also essential. Emerging therapies include PCSK9 inhibitors for patients who do not reach LDL goals and anti-inflammatory agents.
The impact of modern BMT on stroke risk is profound. The annual stroke risk in patients with asymptomatic carotid stenosis treated with contemporary BMT is estimated to be between 0.5% and 1.0%, a significant reduction from the 2-3% annual risk observed during the era of earlier trials. This decline is supported by data from the Oxford Vascular Study and other contemporary cohorts. When the annual stroke risk is below 1%, the number needed to treat (NNT) with CEA to prevent one stroke over five years becomes very high, exceeding 50 to 100.
<image>Bar graph comparing annual stroke risk in asymptomatic carotid stenosis across different eras: ACAS medical arm (1990s), ACST-1 medical arm (2000s), and contemporary best medical therapy (2020s), showing the progressive decline from approximately 2.3% to 0.5-1.0% per year</image>
Contemporary Trials
The CREST-2 trial is a randomized study comparing CEA plus BMT versus BMT alone, and CAS plus BMT versus BMT alone, in patients with asymptomatic stenosis of 70% or greater. This trial employs modern imaging-based enrollment criteria and optimized medical therapy. Its primary endpoint is stroke or death at four years. Although enrollment has been completed, results are still pending. CREST-2 is expected to significantly influence clinical practice by addressing whether revascularization provides benefit beyond optimal medical therapy.
The ACST-2 trial, published in 2023, randomized 3,625 patients with asymptomatic stenosis to either CEA or CAS, both combined with BMT. The primary finding was that CEA and CAS are equivalent for asymptomatic disease. The five-year non-perioperative stroke rates were 2.7% for CEA and 2.5% for CAS, while periprocedural stroke or death rates were 2.4% for CEA and 2.5% for CAS. Importantly, ACST-2 did not include a BMT-only arm, so it does not answer whether intervention is superior to medical therapy alone. However, it confirms that when perioperative risk is low, CAS and CEA have comparable outcomes in asymptomatic patients.
The ECST-2 trial is ongoing and compares revascularization (CEA or CAS) plus BMT versus BMT alone. It uses a risk scoring model to identify patients most likely to benefit from intervention and is expected to help define which patients should undergo revascularization.
Patient Selection: Identifying High-Risk Subgroups
Certain patients with asymptomatic carotid stenosis may still benefit from intervention. These include those with high-grade stenosis of 70-80% or greater accompanied by high-risk plaque features. Echolucent or vulnerable plaques identified on ultrasound or MRI, such as intraplaque hemorrhage (IPH) on MRI—which is a strong predictor of future events—and low gray-scale median on ultrasound, indicate increased risk. The presence of microembolic signals detected by transcranial Doppler (TCD) monitoring, progressive stenosis on serial imaging, impaired cerebrovascular reserve assessed by TCD with CO2 reactivity or acetazolamide challenge, contralateral internal carotid artery (ICA) occlusion, silent brain infarcts ipsilateral to the stenosis on MRI, and ulcerated plaques on imaging also suggest higher risk and potential benefit from intervention.
Conversely, patients best managed with BMT alone typically have moderate stenosis (50-69%) with stable plaque morphology, heavily calcified and echogenic plaques that confer low embolic risk, limited life expectancy (less than 3 to 5 years), high surgical or procedural risk, or express patient preference after informed shared decision-making.
Emerging risk prediction models aim to personalize treatment decisions. These include carotid plaque MRI risk scoring, multimodal assessments combining plaque morphology, hemodynamic reserve, and emboli detection, as well as machine learning algorithms that integrate clinical and imaging data.
<image>Decision-making algorithm for asymptomatic carotid stenosis in the modern era, showing the initial assessment with duplex ultrasound, plaque imaging with MRI, emboli detection with TCD, and cerebrovascular reserve testing, leading to risk stratification into high-risk (consider intervention) versus low-risk (optimal medical therapy with surveillance) categories</image>
Plaque Imaging Advances
MRI plaque imaging has advanced the ability to identify high-risk features. Intraplaque hemorrhage (IPH) appears as a T1-hyperintense signal and is the strongest imaging predictor of future cerebrovascular events. Patients with IPH have an annual stroke risk of 5-7% even if asymptomatic, suggesting they may represent a subgroup that benefits most from intervention. High-resolution MRI can also visualize thin or ruptured fibrous caps and identify large lipid-rich necrotic cores, both markers of plaque vulnerability.
Contrast-enhanced ultrasound (CEUS) uses microbubble contrast to detect neovascularization and inflammation within the plaque, which are markers of instability. CEUS is non-invasive and does not involve radiation exposure.
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) identifies metabolically active, inflamed plaques by their uptake of FDG. While this technique predicts future cardiovascular events, it remains primarily a research tool and is not widely used in clinical practice.
Shared Decision-Making
Shared decision-making is central to managing asymptomatic carotid stenosis. Patients must understand the natural history of the condition under modern medical therapy, which carries a low annual stroke risk. They also need to be informed about the risks and benefits of intervention options such as CEA, CAS, or TCAR, as well as the necessity of lifelong medical therapy and risk factor control regardless of whether they undergo a procedure. The role of surveillance and plaque monitoring should also be discussed. Surgeons have an obligation to present unbiased information and avoid operating on patients unlikely to benefit.
Clinical Pearls
The annual stroke risk with modern best medical therapy for asymptomatic carotid stenosis is likely less than 1%, fundamentally altering the risk-benefit calculus of intervention. Not all asymptomatic stenoses are equivalent; plaque morphology is more important than stenosis percentage alone. Intraplaque hemorrhage detected on MRI may be the most critical imaging biomarker for identifying high-risk patients who might benefit from intervention. The ACST-2 trial confirms that CEA and CAS are equivalent for asymptomatic disease, but the key question—whether either intervention is superior to best medical therapy alone—awaits answers from CREST-2 and ECST-2. Every patient with asymptomatic carotid stenosis should receive maximal medical therapy regardless of the decision to intervene. Shared decision-making is essential, marking the end of the era when every 70% stenosis was automatically treated surgically. While awaiting CREST-2 results, current evidence supports a more conservative and individualized approach.
References
- Halliday A, et al. Second asymptomatic carotid surgery trial (ACST-2). Lancet. 2021;398(10305):1065-1073.
- Naylor AR, et al. ESVS 2023 Clinical Practice Guidelines on Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023;65(1):7-111.
- Marquardt L, et al. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment. Stroke. 2010;41(1):e11-e17.
- Spence JD. Asymptomatic carotid stenosis: mainly a medical condition. Vascular. 2016;24(5):549-557.
- Singh N, et al. The role of MRI plaque imaging in assessing asymptomatic carotid stenosis. Eur J Vasc Endovasc Surg. 2021;61(5):678-689.
